ReviewAustralian prescriber2015
Concerns about quetiapine.
Review in Australian prescriber, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evergreening of Psychiatric Medications: A Systemic Literature Review of Strategies, Case Examples, and the Implications of Cost.Community mental health journal · 2023Pooled it
- Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum Concentration and Clinical Presentation-Structured Literature Review and Analysis.Journal of xenobiotics · 2024Review
- The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy.International journal of molecular sciences · 2024Review
- Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017.JCPP advances · 2024Article
- Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Ongoing challenges of off-label prescribing.Australian prescriber · 2023Review
- Patterns of suboptimal antipsychotic use and misuse in Australia: What can routinely collected data tell us?British journal of clinical pharmacology · 2023Article
- Characteristics and predictors of off-label use of antipsychotics in general population sample.Acta psychiatrica Scandinavica · 2022Article
- Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients.Zdravstveno varstvo · 2018Article
- The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians.CMAJ open · 2018Article
- Antipsychotic Drug Dispensations in Older Adults, Including Continuation After a Fall-Related Hospitalization: Identifying Adherence to Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria Using the Nova Scotia Seniors' Pharmacare Program and Canadian Institute for Health's Discharge Databases.Current therapeutic research, clinical and experimental · 2018Article
- The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015.European journal of clinical pharmacology · 2017Article
- Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior?Journal of research in pharmacy practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quetiapine is subsidised by the Pharmaceutical Benefits Scheme to treat schizophrenia and bipolar disorder. An extended-release formulation is also approved for use, but not subsidised, for treatment-resistant depression and generalised anxiety disorder. There is increasing off-label prescribing of quetiapine for indications such as insomnia that have little evidence to support them. This prescribing is often for at-risk patients, such as people with personality or social vulnerabilities and those at risk of metabolic complications or cardiovascular events. More evidence is required to support prescribing decisions regarding these off-label indications. In the meantime prescribers should be supported with alternatives to prescribing for these conditions, such as psychological therapies that have a better evidence base and safety record.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.